WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 555929
CAS#: 218457-67-1
Description: CB-103 is a γ-secretase inhibitor. CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis, thereby impairing proliferation, including in GSI-resistant human tumor cell lines with chromosomal translocations and rearrangements in Notch genes. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts, notably without causing the dose-limiting intestinal toxicity associated with other Notch inhibitors.
MedKoo Cat#: 555929
Name: CB-103
CAS#: 218457-67-1
Chemical Formula: C15H18N2O
Exact Mass: 242.1419
Molecular Weight: 242.322
Elemental Analysis: C, 74.35; H, 7.49; N, 11.56; O, 6.60
Synonym: CB-103; CB 103; CB103;
IUPAC/Chemical Name: 5-Amino-2-(4-tert-butylphenoxy)pyridine
InChi Key: WHIWGRCYMQLLAO-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3
SMILES Code: CC(C)(C)C1=CC=C(C=C1)OC2=NC=C(C=C2)N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 50.0 | 206.63 |
The following data is based on the product molecular weight 242.322 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Fabbro D, Bauer M, Murone M, Lehal R. Notch Inhibition in Cancer: Challenges and Opportunities. Chimia (Aarau). 2020 Oct 28;74(10):779-783. doi: 10.2533/chimia.2020.779. PMID: 33115560.
2: Lehal R, Zaric J, Vigolo M, Urech C, Frismantas V, Zangger N, Cao L, Berger A, Chicote I, Loubéry S, Choi SH, Koch U, Blacklow SC, Palmer HG, Bornhauser B, González-Gaitán M, Arsenijevic Y, Zoete V, Aster JC, Bourquin JP, Radtke F. Pharmacological disruption of the Notch transcription factor complex. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16292-16301. doi: 10.1073/pnas.1922606117. Epub 2020 Jun 29. PMID: 32601208; PMCID: PMC7368267.
